SEARCH

SEARCH BY CITATION

References

  • 1
    Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drug. N Engl J Med 1994; 331: 12721285.
  • 2
    Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol 2007; 56: 181200.
  • 3
    Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149153.
  • 4
    Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mochenhaupt M. Effect of treatments on the motality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58: 3340.
  • 5
    Bachot N, Revus J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003; 139: 3336.
  • 6
    Mochenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnosis and therapy. J Dtsch Dermatol Ges 2009; 7: 142160.
  • 7
    Egan CA, Grant WJ, Morris SE, Saffle JR, Zone JJ. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999; 40: 458461.
  • 8
    Gerasimos B, Natse T, Christidou F et al. Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher 2002; 6: 225228.
  • 9
    Yamada H, Takamori K, Yaguchi H, Ogawa H. A study of the efficacy of plasmapheresis for the treatment of drug induced toxic epidermal necrolysis. Ther Apher 1998; 2: 153156.
  • 10
    Gerard A, Schooneman F, Roche G et al. Lyell’s syndrome: treatment by plasma exchange. Plasma Ther Transfus Technol 1984; 5: 259260.
  • 11
    Wada N, Yamada H, Ozawa Y, Masuda T. A case of drug indused toxic epidermal necrolysis successfully treated with double filtration plasmapheresis. Jpn J Clin Dermatol 1997; 51: 517520 (in Japanese).
  • 12
    Takimoto R, Takamori K. Plasmapheresis in toxic epidermal necrolysis. Jpn J Clin Dermatol 2002; 56: 103105 (in Japanese).
  • 13
    Nakata K, Hirasawa H, Oda S et al. Two cases of toxic epidermal necrolysis treated with plasma exchange. J Jpn Assoc Acute Med 2003; 14: 273278 (in Japanese).
  • 14
    Mizutani K, Hashimoto T, Tamada Y, Matsumoto Y. A case of toxic epidermal necrolysis successfully treated with plasma exchange. Jpn J Clin Dermatol 2004; 58: 539541 (in Japanese).
  • 15
    Lissia M, Figus A, Rubino C. Intravenous immunogloblins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br J Plast Surg 2005; 58: 504510.
  • 16
    Nakata K, Hirasawa H, Oda S, Shiga H. Toxic epidermal necrolysis. Jpn J Acute Med 2004; 28: 11611164 (in Japanese).
  • 17
    Takimoto R, Takamori K. Drug induced toxic epidermal necrolysis. Jpn J Clin Med 2004; 62: 515518 (in Japanese).
  • 18
    Okuyama Y, Yamada H, Ikeda S. Plasmapheresis for the treatment of toxic epidermal necrolysis. Jpn J Apher 2008; 27: 139144 (in Japanese).
  • 19
    Turner MS, Sutton D, Sauder DN. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol 2000; 43: 10581064.
  • 20
    Martin LK, Murrell DF. Treatment of pemphigus. The need for more evidence. Arch Dermatol 2008; 144: 100101.
  • 21
    Kodama K, Kuno H, Koide M, Matsuo T. Virus-associated haemophagocytic syndrome responsive to steroid pulse therapy and double-filtration plasmapheresis. Clin Lab Haemotol 2000; 22: 179181.
  • 22
    Fenwick JC, Cameron M, Naiman SC et al. Blood transfusion as a cause of leucocytosis in critically ill patient. Lancet 1994; 344: 855856.
  • 23
    Craddock PR, Fehr J, Dalmasso AP et al. Hemodialysis leucopenia. J Clin Invest 1977; 59: 879888.
  • 24
    Hanger RE, Hunziker T, Buettiker U et al. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol 2005; 116: 923924.
  • 25
    Paniagua RT, Sharpe O, Ho PP et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 2006; 116: 26332642.